BRPI0507464A - formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida - Google Patents

formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida

Info

Publication number
BRPI0507464A
BRPI0507464A BRPI0507464-9A BRPI0507464A BRPI0507464A BR PI0507464 A BRPI0507464 A BR PI0507464A BR PI0507464 A BRPI0507464 A BR PI0507464A BR PI0507464 A BRPI0507464 A BR PI0507464A
Authority
BR
Brazil
Prior art keywords
salt
methyl
phenyl
methylpiperazin
ylamino
Prior art date
Application number
BRPI0507464-9A
Other languages
English (en)
Inventor
Hans Michael Buerger
Paul William Manley
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0507464A publication Critical patent/BRPI0507464A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

FORMAS DE SAL DE 4-(4-METILPIPERAZIN-1-ILMETIL)-N-¢4-METIL-3-((-PIRIDIN-3-IL)P IRIMIDIN-2-ILAMINO)FENIL!-BENZAMIDA. A presente invenção refere-se a sais de adição de ácido de 4-¢(4-metil-1-piperazinil)metil!-N-¢4-metil-3-¢¢4-(3-piridinil)-2-pirimidinil!a mino!fenil!-benzamida, selecionados do grupo consistindo em um sal tartarato, tal como (D)(-) ou um sal tartarato (L) (+), um sal cloridrato, um sal citrato, um sal maleato, um sal fumarato, um sal succinato, um sal benzoato, um sal benzenossulfonato, um sal pamoato, um sal formiato, um salmalonato, um sal 1,5-naftalenodissulfonato, um sal salicilato, um sal cicloexanodisulfamato,um sal, lactato um sal mandelato, um sal glutarato aquoso, um sal adipato, um sal esquarato, um sal vanilato, um sal oxaloacetato, um sal ascorbatoe um sal sulfato.
BRPI0507464-9A 2004-02-04 2005-02-03 formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida BRPI0507464A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04
PCT/EP2005/001077 WO2005075454A2 (en) 2004-02-04 2005-02-03 SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE

Publications (1)

Publication Number Publication Date
BRPI0507464A true BRPI0507464A (pt) 2007-07-10

Family

ID=34837520

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507464-9A BRPI0507464A (pt) 2004-02-04 2005-02-03 formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida

Country Status (22)

Country Link
US (3) US20080249104A1 (pt)
EP (1) EP1713792B1 (pt)
JP (1) JP4937760B2 (pt)
KR (2) KR20060135735A (pt)
CN (1) CN100558723C (pt)
AR (1) AR047530A1 (pt)
AU (1) AU2005211514B2 (pt)
BR (1) BRPI0507464A (pt)
CA (1) CA2553887C (pt)
EC (1) ECSP066752A (pt)
IL (1) IL177005A (pt)
MA (1) MA28428B1 (pt)
MY (1) MY144177A (pt)
NO (1) NO20063942L (pt)
NZ (1) NZ548714A (pt)
PE (1) PE20051096A1 (pt)
PH (1) PH12013500157A1 (pt)
RU (1) RU2375355C2 (pt)
TN (1) TNSN06243A1 (pt)
TW (1) TWI347186B (pt)
WO (1) WO2005075454A2 (pt)
ZA (1) ZA200605972B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1960380A1 (en) 2005-11-25 2008-08-27 Novartis AG F,g,h,i and k crystal forms of imatinib mesylate
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
KR101041203B1 (ko) 2007-09-25 2011-06-13 테바 파마슈티컬 인더스트리즈 리미티드 안정한 이매티닙 조성물
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
TW202241853A (zh) 2009-01-16 2022-11-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
EP4124616A1 (en) 2009-06-25 2023-02-01 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011036305A2 (en) 2009-09-28 2011-03-31 Medizinische Universität Wien New use of pdgfrbeta inhibitors
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
CA2792472A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
EA024088B1 (ru) 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
US20150057321A1 (en) 2012-04-04 2015-02-26 Intervet Inc. Soft chewable pharmaceutical products
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
EA035891B1 (ru) 2016-01-25 2020-08-27 КРКА, д.д., НОВО МЕСТО Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3691861B2 (ja) * 1994-09-14 2005-09-07 株式会社東芝 光ディスク用光パルス幅制御装置
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
PT1487424E (pt) * 2002-03-15 2007-01-31 Novartis Ag 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-il-amino)fenil]-benzamida para o tratamento doenças mediadas por ang ii
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
EP1960380A1 (en) * 2005-11-25 2008-08-27 Novartis AG F,g,h,i and k crystal forms of imatinib mesylate

Also Published As

Publication number Publication date
ZA200605972B (en) 2007-11-28
EP1713792A2 (en) 2006-10-25
KR20060135735A (ko) 2006-12-29
RU2006131548A (ru) 2008-03-10
IL177005A0 (en) 2006-12-10
NZ548714A (en) 2009-08-28
TNSN06243A1 (en) 2007-12-03
CA2553887A1 (en) 2005-08-18
TWI347186B (en) 2011-08-21
CN1914191A (zh) 2007-02-14
US20120142697A1 (en) 2012-06-07
JP2007520518A (ja) 2007-07-26
KR20120127525A (ko) 2012-11-21
PH12013500157A1 (en) 2014-09-08
MY144177A (en) 2011-08-15
RU2375355C2 (ru) 2009-12-10
AU2005211514A1 (en) 2005-08-18
ECSP066752A (es) 2006-11-16
TW200529854A (en) 2005-09-16
PE20051096A1 (es) 2006-01-23
AU2005211514B2 (en) 2009-09-10
NO20063942L (no) 2006-11-02
AR047530A1 (es) 2006-01-25
JP4937760B2 (ja) 2012-05-23
IL177005A (en) 2014-05-28
WO2005075454A2 (en) 2005-08-18
US20140051853A1 (en) 2014-02-20
WO2005075454A3 (en) 2006-07-27
EP1713792B1 (en) 2014-04-30
US8513256B2 (en) 2013-08-20
CA2553887C (en) 2013-04-16
US20080249104A1 (en) 2008-10-09
MA28428B1 (fr) 2007-02-01
CN100558723C (zh) 2009-11-11

Similar Documents

Publication Publication Date Title
BRPI0507464A (pt) formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida
WO2005095379A3 (en) Crystalline methanesulfonic acid addition salts of imatinib
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
TR200701870T1 (tr) İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20170697A1 (es) Indazoles sustituidos con benzilo como inhibidores de bub1
SG154451A1 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
RS51592B (en) SOLID PREPARATION CONTAINING ALOGLIPTIN AND PIOGLITAZONE
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
WO2009065910A3 (en) Acid addition salts of imatinib and formulations comprising the same
ATE339197T1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
DE602007011756D1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
MX2021002875A (es) Formas cristalinas de un compuesto de quinazolina y sus sales clorhidrato.
BR0307286A (pt) Tratamento de artrite reumatóide usando imatinib
DK1807401T3 (da) Fremgangsmåde til fremstilling af phenyl-2-pyrimidinylketoner samt deres nye mellemprodukter
ATE411299T1 (de) Chlorsubstituierte guanidine
DE602004022540D1 (de) Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
DE602005025514D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
NZ602758A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
TH74677A (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
TH114424A (th) สารเตรียมชนิดของแข็ง
PL366885A1 (en) Method for manufacturing crystalline form alpha of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-n-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
MX2007000892A (es) Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.